MaaT Pharma Announces Initiation of Coverage of its Stock by KBC Securities, Kempen and Portzamparc/Groupe BNP ParibasJanuary 13, 2022
LYON, France–(BUSINESS WIRE)–$MAAT–Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company“), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, announces the initiation of coverage of its stock by KBC Securities, Kempen and Portzamparc / Groupe BNP Paribas.
With a research report named “Échec et MaaT pour le cancer”, Portzamparc / Groupe BNP Paribas today initiates coverage of MaaT Pharma with a Buy recommendation.
This coverage of MaaT Pharma stock comes in addition to the ones initiated in December 2021 by brokerage firms KBC Securities with a Buy recommendation (research report “More than a Gut Feeling”) and Kempen, also with a Buy recommendation (research report “No Guts no Glory”).
Next financial communication:
- February 28th, 2022, after stock market closes: publication of the 2021 revenues and cash position as of December 31st, 2021.
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in a Phase II clinical trial in acute GvHD. Our powerful discovery and analysis platform, gutPrint®, supports the development and expansion of our pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions.
The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.
MaaT Pharma is listed on Euronext Paris (ticker: MAAT).
Co-Founder and CEO
Siân Crouzet, COO/ CFO
+33 4 28 29 14 00
Senior PR & Corporate Communications Manager
+33 6 07 55 25 36
Jacob VERGHESE or
+49 89 23 88 77 31